**Gut microbiome, obesity, and metabolic dysfunction**

Herbert Tilg¹ and Arthur Kaser²

¹Christian Doppler Research Laboratory for Gut Inflammation, Medical University Innsbruck, Innsbruck, Austria.
²Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

The prevalence of obesity and related disorders such as metabolic syndrome has vastly increased throughout the world. Recent insights have generated an entirely new perspective suggesting that our microbiota might be involved in the development of these disorders. Studies have demonstrated that obesity and metabolic syndrome may be associated with profound microbital changes, and the induction of a metabolic syndrome phenotype through fecal transplants corroborates the important role of the microbiota in this disease. Dietary composition and caloric intake appear to swiftly regulate intestinal microbial composition and function. As most findings in this field of research are based on mouse studies, the relevance to human biology requires further investigation.

**Introduction**

The prevalence of obesity and the associated disorders metabolic syndrome and type 2 diabetes (T2D) have increased substantially worldwide over the last decades. Obesity increases risk for many other diseases such as atherosclerosis, nonalcoholic fatty liver disease, and certain cancers. Recent insight suggests that the intestinal microbial flora could play an important role in obesity and its related diseases.

The human intestine harbors an enormously complex, diverse, and vast microbial community, referred to as gut microflora or microbiota (1–4). The human gut microbiota is estimated to consist of at least 10^{14} bacteria and archaea, composed of approximately 1,100 prevalent species, with approximately 160 such species per individual. In its entirety, the microflora is estimated to contain 150-fold more genes than our own host genomes (5). Apart from contributing substantial beneficial functions to the host (e.g., digestion of otherwise indigestible plant polysaccharides), this separate ecosystem has enormous potential for physiological and pathological interactions with the host; for example, we have already learned that the microbiota drives the development of the mucosal and systemic immune system and controls the regeneration of the intestinal epithelium (6, 7).

The development of obesity and the metabolic syndrome is a complex process involving genetic and environmental factors and is associated with pathways that connect metabolism with the immune system and vice versa (8–15). Important studies on the relationship of the intestinal microbial flora with obesity have uncovered profound changes in the composition and metabolic function of the gut microbiota in obese individuals (16–19), which appear to enable the “obese microbiota” to extract more energy from the diet (20). Moreover, these studies have demonstrated that the gut microbiota interacts with host epithelial cells to indirectly control energy expenditure and storage (16).

Genetic investigations have identified multiple genes that confer increased risk for obesity that individually may have comparatively modest effects on hunger, satiety, and food intake (21–23). However, these minor effects may be amplified in the current environment, in which, in many parts of the world, nearly unlimited amounts of food have been available during the last decades. In this article we will discuss current evidence on how the intestinal microbiota might have a profound role in the development of obesity and the metabolic syndrome and thereby could contribute to the obesity epidemic.

**Gut microbiota in animal and human obesity: evidence of disturbance**

New molecular, culture-independent techniques that are based on microbial DNA sequencing have profoundly transformed our ability to study microbial communities (24, 25). These techniques have demonstrated that the mammalian gut microbiota belongs predominantly to four bacterial phyla: the Gram-negative Bacteroidetes and Proteobacteria and the Gram-positive Actinobacteria and Firmicutes. Initial evidence for an altered microflora associated with obesity came from studies in the leptin-deficient ob/ob mouse model. 16S rRNA sequencing of the distal gut microbiota of ob/ob mice, lean ob/+ mice, and wild-type siblings and their ob/+ mothers, all fed the same diet, revealed that ob/ob mice exhibit a major reduction in the abundance of Bacteroidetes and a proportional increase in Firmicutes (17).

Feeding of a high-fat/high-polysaccharide diet to genetically wild-type rodents led to similar microbial changes (26). Confounding factors affecting microbial composition and function may include diet per se (discussed below), the use of antibiotics (and other drugs), which substantially reduce bacterial diversity (27), and possibly effects related to the genetic background of animal models (28).

Consistent with animal models, Ley et al. observed analogous differences with an increase in the ratio of Firmicutes/Bacteroidetes in the distal gut microbiota in human obesity (29). Another study demonstrated that Firmicutes were dominant in lean and obese individuals and decreased in 3 patients undergoing Roux-en-Y gastric bypass surgery (30). In contrast to earlier studies, Zhang et al. (30) described that Prevotellaceae, a subgroup of Bacteroidetes, are significantly enriched in obesity, again raising the potentially important issue of diet as a confounding factor, as the patients in the Ley study (29) were either on a fat-restricted or carbohydrate-restricted diet, whereas in the Zhang study, researchers did not limit dietary components. Another study also described a decrease of Bacteroidetes in obesity and an increase in
**Firmicutes** (e.g., *Lactobacilli*) (31). Overweight pregnant patients (week 24) also have reduced numbers of *Bifidobacteria* and *Bacteroidetes*, whereas increased numbers of certain *Firmicutes* (e.g., *Staphylococcus*) or *Proteobacteria* (e.g., *Enterobacteriaceae* such as *Escherichia coli*) were detected (32). However, it is worthwhile to note that the aforementioned “typical” changes in the gut microbiota in human obesity have not been found by all investigators (33, 34). Schwiertz and colleagues reported even lower ratios of *Firmicutes* to *Bacteroidetes* in obese human adults compared with lean controls (33). Another study also observed no differences between obese and non-obese subjects in the number of *Bacteroidetes* measured in fecal samples, and no significant changes using weight loss diets. However, significant diet-dependent reductions in a group of butyrate-producing *Firmicutes* were found (34). A fascinating paper has been recently presented by Arumugam et al. (35) investigating the phylogenetic composition of 39 fecal samples from individuals representing 6 nationalities. Combining those data with previously published data sets, the authors characterized three clusters of individual microbiotal composition referred to as enterotypes that were not nation- or continent-specific. Interestingly, their results did not reveal any correlation between body mass index and the *Firmicutes/Bacteroidetes* ratio. Their analysis, however, suggested that metagenomic-derived functional biomarkers might be more important than phylogenetic ones, as they identified three marker molecules that correlate strongly with the host’s body mass index, two of which are ATPase complexes, supporting the link found between energy harvest and obesity in the host (20). Varying data in several human studies further stress the importance of potential confounding factors such as diet or day-to-day variability in microbiota makeup, and the need for well-controlled study designs. Whereas a few studies have observed an increase in the *Firmicutes/Bacteroidetes* ratio (29, 31, 32), others have failed to demonstrate such a correlation (30, 33–35). Therefore, differences at the phylum level are probably less important than metagenomic-based functional aspects.

**Energy harvest affected by the microbiota**

The gut microbiota benefits the host in numerous ways, among them contributing the capability to extract calories from otherwise indigestible common polysaccharides in the diet (36) via enzymes such as glycoside hydrolases and others that are not encoded within the human genome (37, 38). Studies in germ-free mice revealed that the gut microbiota enhances adiposity mainly by increased energy extraction from food and by regulating fat storage (16, 39), and germ-free mice are protected from obesity and metabolic syndrome (16, 17, 40). Specifically, conventionalization (the restoration of conventional intestinal flora) of germ-free mice resulted in a substantial increase in body fat, hepatic triglycerides, fasting plasma glucose, and insulin resistance. The presence of a microbial population enhanced intestinal monosaccharide uptake, resulting in increased de novo lipogenesis and accumulation of hepatic and adipose tissue triglycerides. Apart from these general

**Figure 1**

Microbiota regulates host metabolic functions. The microbiota controls host physiology at multiple levels. Microbial metabolic products such as SCFAs bind to GPCRs on intestinal epithelial cells (for example, Gpr41 and Gpr43) to control energy balance, partly via the gut-derived hormone Pyy, and also to control the inflammatory responsiveness of the host. Tlr5 activation (e.g., through bacterial flagellin) presumably on epithelial or myeloid cells profoundly affects the structural composition of the intestinal microbiota, which in turn regulates appetite, weight gain, and insulin sensitivity through unknown mechanisms. Microbial signals also regulate Fiaf release from intestinal epithelial cells, which acts as an inhibitor of Lpl and thereby regulates peripheral fat storage. Through another unknown mechanism, the microbiota also regulates the energy gauge in the liver and muscle through the phosphorylation of Ampk. Glp2 ascertains epithelial barrier function, and a leaky barrier leads to exposure and activation of myeloid cells in response to microbial signals such as the Tlr4 ligand endotoxin. Fiaf, fasting-induced adipose factor; Glp2, glucagon-like peptide-2; Gpr41/43, G-protein coupled receptor; Lpl, lipoprotein lipase; Pyy, peptide YY; SCFA, short chain fatty acids.
effects of the microbiota on food utilization, ob/ob mice have been reported to harvest energy from food more efficiently than lean wild-type animals (41). A metagenomic sequencing analysis and metabolic pathway reconstruction of the distal intestinal flora of ob/ob mice revealed that the changes in the relative abundance of Bacteroidetes and Firmicutes were associated with a switch in the metabolic potential of the microbiota that conferred the ob/ob gut microbiome an increased capacity to harvest energy from the diet (20). Remarkably, this trait of obesity was transmissible through fecal transplants from obese (as compared to non-obese) to germ-free mice (20, 26). Ob/ob mice also harbor more methanogenic archaea, which may increase efficiency of bacterial fermentation via removal of H₂ (20). Studies with Methanobrevibacter smithii, and Bacteroides thetaiotaomicron revealed that co-colonization not only enhanced efficiency, but also changed the specificity of bacterial polysaccharide fermentation, increasing adiposity compared with mice colonized with either organism alone (42).

Further studies have revealed additional complexities related to the potential increased energy harvest from the diet through dietary-induced or genetically induced obese microbiota (43). In this study, the authors showed that both age and diet are important factors not only for the composition of the gut microbiota but also for its potential to extract energy. Experimental protocols that allow colonization of germ-free mice with selective human flora are essential to investigate the effects of various diets and other confounding factors such as age on the microbiota and their consequent implications for host metabolism (44).

**Effects of diet and other factors on the composition of the gut microbiome**

Several lines of evidence suggest that dietary factors might profoundly influence microbiotal composition. Studies in resistin-like molecule β-knockout mice, which are resistant to diet-induced obesity, revealed that dietary factors are the key determinant of microbial composition, and indeed appear more relevant than obesity per se (45). In this study, switching to a high-fat diet resulted in a decrease in Bacteroidetes, whereas the numbers of Firmicutes and Proteobacteria increased. Importantly, this was observed in both the presence and absence of obesity, clearly suggesting that diet must be considered as a confounding factor affecting microbial composition. In another study, fresh or frozen adult human fecal microbial communities from lean donors were transplanted into germ-free C57BL/6J mice (44). These microbiially humanized mice established a stable and heritable microbiota that reproduced much of the bacterial diversity of the donor’s microbiota. A change in the diet (i.e., from a low-fat, plant polysaccharide to a high-fat, high-sugar diet) shifted the structure of the microbiota within a single day, along with changes in metabolic pathways in the microbiome. When fed a Western diet, these microbiobially humanized mice exhibited increased adiposity, and this trait was transferable via microbiota transplantation (44). The genetic background of our microbiota might determine how certain dietary factors are handled. Genetic and functional differences between Bacteroides spp. are predictive how these bacteria utilize fructans, a class of fructose-based polysaccharides (46). Undoubtedly, diet critically affects the gut microbiome, changes occur very rapidly, and adiposity might be transferable by fecal transplantation.

The intestinal microbiota from children ingesting a modern Western diet and a rural African diet may differ on the same basis (47). Children from Burkina Faso showed a significant enrichment in Bacteroidetes and a depletion of Firmicutes, with a significant abundance of bacteria from the genus Prevotella and Xylo-bacter, which are known to encode genes enabling hydrolysis of cellulose and xylan. These African children indeed demonstrated a higher content of short-chain fatty acids (SCFAs). Gut microbiota in rural Africa may allow individuals to maximize energy intake from fibers while protecting from inflammation and infection (47). Genetic and environmental factors may have also contributed significantly to the dramatic differences in gut microbiome composition observed in these children.

Besides diet, genetic and other environmental factors may shape the gut’s microbiota. Benson et al. found in mice a core measurable microbiota of 64 taxonomic groups that varied across most animals, largely dependent on individual host genotype (48). This study identified host quantitative trait loci able to control individual microbial species. The complexity of factors affecting the gut microbiome early in life has been convincingly demonstrated in a recent study by Koenig et al. (49). Most “chaotic shifts” in the microbiome were associated with exceptional life events, and interestingly, species harboring functional genes involved in the fermentation of plant polysaccharides were even present before the introduction of solid foods. Overall, phylogenetic diversity seems to develop gradually over time. These studies are in accordance with the recent finding that obese and lean twins share a core microbiome at the gene rather than at the phylum level (40).

**Obesity, microbiota, and epithelial integrity**

Some lines of experimental evidence suggest that high-fat diets may affect epithelial integrity and hence lead to impaired gut permeability, and consequently to systemic inflammation via translocation of Tlr ligands (50). Prebiotic carbohydrates and/or antibiotics lowered systemic endotoxin levels and inflammatory cytokine expression in the liver (50). Such improvement of metabolic inflammation in obese mice might not only involve changes in the microbiota, but also expression of glucagon-like peptide 2 (Glp2) (51), an intestinal growth factor with anti-inflammatory activities (52) that stabilizes intestinal barrier function (53). Prebiotic therapy improved intestinal permeability, systemic inflammation, hepatic expression of pro-inflammatory cytokines, and insulin sensitivity in ob/ob mice, which was paralleled by enhanced intestinal Glp2 expression. Treatment of animals with a Glp2 agonist revealed similar beneficial effects (51). The endocannabinoid system has also been shown to potentially mediate the influence of microbiota on gut permeability. Studies involving specific antagonists and agonists demonstrated that the endocannabinoid system controls not only gut permeability but also plasma LPS levels and adipogenesis (54). Endocannabinoids increase mRNA expression of the tight junction protein occludin-1 and decrease expression of claudin-1, further supporting a potential role in the regulation of intestinal permeability (55).

Sprague-Dawley rats typically present either with an obesity-prone or an obesity-resistant phenotype. This model therefore could be an attractive way to dissect diet from associated obesity/ inflammation. When fed a high-fat diet, only the obesity-prone rats show an increase in ileal Tlr4 expression associated with ileal inflammation (56). Furthermore, intestinal permeability and serum endotoxin levels were increased in obesity-prone, but not obesity-resistant rats. However, the diet induced identical microbiota changes in both groups. Hence, although a high-fat diet may affect the microbiota, other (host) factors might determine inters-
tinal barrier function and induction of local/systemic inflammation. Indeed, multiple interactions between certain dietary factors, the microbiota, or their products and the innate immune system may take place and affect barrier function. For example, dietary wheat gluten proteins (gliadin) decrease the number of goblet cells in the small intestine, especially in conjunction with certain intestinal bacteria (e.g., Escherichia coli), and lead to impairment of tight junctions (57). Antibiotic therapy may be another factor affecting epithelial integrity, as treatment with metronidazole reduces mucus thickness and thereby predisposes mice to exacerbated Citrobacter rodentium–induced colitis (58). Furthermore, widespread use of antibiotics in early life has been suggested as a link to the obesity epidemic (4).

However, it remains to be unambiguously determined whether gastrointestinal barrier function is indeed impaired in human obesity. In fact, a recent study on 13 obese and 11 control subjects did not find evidence of impaired barrier function despite systemically elevated levels of C-reactive protein, a measure of inflammation (59). Further studies are needed to better define epithelial integrity in human obesity and its potential role in the microbiota.

Gut microbiota regulate host genes that control metabolic processes
Colonization of germ-free mice substantially alters transcription of various mediators in the intestine (particularly in epithelial cells), thereby regulating key intestinal functions such as nutrient absorption, mucosal barrier function, metabolic functions, and angiogenesis (60). Fasting-induced adipose factor (Fiaf; also known as angiopeptin-like protein 4) is a circulating lipoprotein lipase (Lpl) inhibitor produced by the intestine, liver, and adipose tissue (61). Conventionalization of germ-free mice suppresses expression of Fiaf in gut epithelial cells (16). Increased adipocyte Lpl activity results in increased cellular uptake of fatty acids and adipocyte triglyceride accumulation. Germ-free Fiaf–/– mice contain the same amount of total body fat weight as conventionalized (i.e., Fiaf-suppressed) mice, suggesting that Fiaf is a mediator of microbial regulation of energy storage (16). In contrast, mice fed a high-fat diet complemented with Lactobacillus paracasei exhibited significantly reduced body fat, which was paralleled by increased circulating levels of Fiaf (62). Lactobacillus paracasei indeed upregulated Fiaf expression in colonic epithelial cell lines, and oral inoculation of germ-free mice with this species resulted in increased circulating Fiaf levels (62). Hypothalamic Fiaf expression is regulated by physiological appetite regulators and mediates their anorexigenic effects via inhibition of hypothalamic AMPK activity. Therefore, Fiaf appears to have an important role in central regulation of energy metabolism (63). Manipulation of Fiaf by the microflora seems to be a prototypic model of its remote control of host physiology (Figure 1).

Another pathway that has been suggested to account for the consistently lean phenotype of germ-free mice on a high-fat diet involves Ampk (39). Ampk is a key enzyme conserved from yeast to humans and acts as a fuel gauge that controls cellular energy status (64). The lean phenotype of germ-free mice on a Western diet is associated with increased levels of phosphorylated Ampk in skeletal muscle and liver, increased levels of its downstream targets involved in fatty acid oxidation, such as acetyl-CoA carboxylase or carnitine-palmitoyltransferase, decreased glycogen storage, and increased hepatic insulin sensitivity (39). Therefore, our microbiota might affect skeletal muscle fatty acid oxidation through metabolic pathways involving Ampk (Figure 1). The exact pathway whereby the microbiota signals to liver or skeletal muscle Ampk is unclear but appears to be independent from Fiaf (39).

A third pathway that influences host energy storage also involves intestinal epithelial cells as sensors of microbial products. The gut microbiota synthesizes a broad spectrum of hydrolases (65) that digest complex dietary carbohydrates to monosaccharides and SCFAs such as acetate, propionate, and butyrate. As end products of bacterial fermentation, these SCFAs represent an important energy source. SCFAs not only diffuse passively into the circulation, but may also act in the gut as signaling molecules. Propionate and acetate are ligands for two G protein–coupled receptors (GPCRs), Gpr41 and Gpr43, mainly expressed by intestinal epithelial cells (66, 67). Conventionally raised Gpr41–/– mice and germ-free Gpr41–/– mice colonized with only Bacteroides thetaiotaomicron and Methanobrevibacter smithii are significantly leaner than wild-type littermates despite similar levels of chow consumption, while there are no differences between wild-type or Gpr41–/– germ-free mice (68). These studies showed that Gpr41 might be a regulator of host energy balance through effects that are dependent upon the gut microbiota and their metabolic capacity (ref. 68 and Figure 1). Upon activation of GPCRs, propionate and acetate induce the release of peptide YY (Pyy). Pyy, an enteroendocrine cell–derived hormone that normally inhibits gut motility and accelerates intestinal transit rate, might be involved in these Gpr41-mediated effects, as Gpr41–/– mice colonized with only Bacteroides thetaiotaomicron and Methanobrevibacter smithii demonstrated increased circulating Pyy levels, an increased transit time, and reduced calorie extraction from the diet (68). Gpr41 also mediates SCFA-induced synthesis of leptin, an adipocytokine with pleiotropic effects on appetite and energy metabolism (69).

SCFAs also act as ligands of Gpr43, and Gpr43–/– mice appear protected from high-fat diet–induced obesity and insulin resistance, at least partly due to Gpr43-regulated energy expenditure (70). Moreover, stimulation of Gpr43 by SCFAs limits inflammation in experimental models of colitis, arthritis, and asthma (71). Germ-free mice, devoid of SCFAs due to the absence of bacteria that would ferment dietary fiber, exhibited exacerbated inflammation in these models, similar to Gpr43–/– mice (71). Gpr43 might provide a molecular link between diet, gastrointestinal bacterial metabolism, and immune and inflammatory responses (71) and could possibly also play some role in colon carcinogenesis (72).

In summary, the gut microbiota affects host energy expenditure and metabolic and immune/inflammatory functions via several pathways. The intestinal epithelium is at the interface between environment, microbiota, and host and plays a substantial and remarkable role in all of these processes.

Microbiota and metabolic syndrome
Metabolic syndrome is thought to develop through the interaction of various genetic and environmental factors. A complex and still poorly characterized interaction between the intestinal microbiota and the innate immune system may be involved in metabolic dysfunction (73). Metabolic syndrome, diabetes, and obesity are characterized by low-grade inflammation, and adipokines play a central role (74). Ob/ob mice treated with antibiotics (norfloxacin and ampicillin) exhibit changes in the microbiota and an improvement in insulin resistance, fasting glycemia, and glucose tolerance compared with control ob/ob mice (75), along with a reduction in systemic “metabolic” endotoxemia and inflammatory parameters (50). In a study involving genetic (apoA-I–deleted) and diet-
induced murine models of metabolic syndrome, in addition to profound overall changes in glucose tolerance, barrier-protective bacterial species (Bifidobacterium spp.) were reduced and endotoxin-producing species (Desulfovibrioacetowe) were increased (76). Diet appeared to be a substantially stronger contributor to structural microbial changes compared with the genetic alteration in this study (76). In addition to regulating insulin sensitivity, the presence or absence of a microbial flora might also regulate cholesterol metabolism (77). Some evidence indicates that T2D, irrespective of obesity, might also affect the structural composition of the microbiota, as might be expected, with differences noted between obese patients and type 2 diabetics (78, 79). T2D might be associated with the dominance of gram-negative bacteria in the gut, such as Bacteroides (80), and in fact a decrease in Bacteroides-Prevotella spp. has been associated with improved metabolic endotoxemia and decreased systemic inflammatory markers in diabetic mice. Specific prebiotics such as oligofructose might affect the structural composition of the microbiota upon high-fat diet feeding, which might improve parameters of metabolic inflammation (80).

A recent report revealed a profound effect of the innate immune receptor, the pattern recognition receptor Tlr5, on structural microbial composition and the consequences for the pathogenesis of metabolic syndrome (81). Th5−/− mice exhibit hyperphagia and develop a metabolic syndrome characterized by hyperlipidemia, hypertension, insulin resistance, and obesity (81). Food restriction prevented many of the metabolic abnormalities observed in Th5−/− mice, but even lean Th5−/− mice exhibited insulin resistance. Notably, metabolic changes in Th5−/− mice resulted in alterations in the composition of the gut microbiota, and transfer of the altered microbiota from Tlr5−/− mice into germ-free wild-type mice conferred a metabolic syndrome phenotype to the latter (ref. 81 and Figure 1). These data not only provide experimental evidence that innate immune signaling is critical in the induction of metabolic syndrome, but notably show that alterations in our intestinal microbiota can be sufficient to induce the metabolic syndrome.

This report, however, has been challenged recently by a study in two different animal colonies with Tlr5 deficiency, where intestinal complexity as compared with the intestinal microbial communities of healthy subjects (17, 20, 29, 87). The recently reported strategy for “humanizing” the murine microbiota (44) might offer great potential to study environmental influences on the microbiome in the context of specific host genotypes.

It is fascinating to speculate that the gut microbiome might contain a critical intestinal trigger linking environment and host in obesity. Fecal transplants have revealed promising results in the treatment of Clostridium difficile infection (88) and could become another interesting option for the therapy of obesity and metabolic syndrome. Indeed, a first small human study on fecal transplantation in patients with metabolic syndrome, though as yet only presented in abstract form, hinted toward improved insulin sensitivity (89). It has to be stated that such an approach might encounter many pitfalls and challenges, such as the complexity of dietary factors, selection and preparation of donors, timing of intervention, current medication, and antibiotic pretreatment. Apart from the likely reservations of patients and physicians, there are still many important questions that must be answered before this can be tested in a broader fashion.

Various host pathways, mainly emanating from epithelial cells, have been characterized in the last years that might mediate the effects of microbiota on metabolism. These factors include Fiaf,
Ampl, Gpr41, Gpr43, Glp2, the endocannabinoid system, and more. The interaction of the intestinal microbial world with its host, and its mutual regulation, will become one of the important topics of biomedical research and will provide us with further insights of the interaction of microbiota, metabolism, metabolic syndrome, and obesity. A better understanding of the interaction between certain diets and our human gut microbiome should help to develop new guidelines for feeding humans at various time points in their life, help to improve global human health, and establish ways to prevent or treat various food-related diseases. Finally, we must be aware that most of the data discussed herein, though fascinating, are based on murine studies commonly using knockout or germ-free animals. Their relevance in human biology will require much more research.

Acknowledgments

Work in the authors’ laboratories is supported by the Christian Doppler Research Laboratory (grant to H. Tilg), the European Research Council (grant 260961; to A. Kaser), and the National Institute for Health Research Cambridge Biomedical Research Centre. The Obesity Review Series is supported in part by unrestricted educational grants from Merck & Co. and the Life Sciences Institute of the University of Michigan.

Address correspondence to: Herbert Tilg, Christian Doppler Research Laboratory for Gut Inflammation, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. Phone: 43 512.504.23374; Fax: 43 512.504.6723374; E-mail: herbert.tilg@i-med.ac.at.

review series

intestinal epithelial barrier function of both tran-
scellular and paracellular pathways in the mouse.

54. Muccioli GG, et al. The endocannabinoid system
links gut microbiota to adipogenesis. Mol Syst Biol.
2010;6:392.

55. Alhamoruni A, Lee AC, Wright KL, Larvin M,
O’Sullivan SE. Pharmacological effects of can-
nabinoids on the Caco-2 cell culture model of
intestinal permeability. J Pharmacol Exp Ther.

56. de la Serre CB, Ellis CI, Lee J, Hartman AL, Rutledge
JC, Raybould HE. Propensity to high-fat diet-induced
obesity in rats is associated with changes in the gut
microbiota and gut inflammation. Am J Physiol Gas-

57. Cinova J, et al. Role of intestinal bacteria in gla-
din-induced changes in intestinal mucosa: study in

the colonic mucus layer and predisposes the host
to exacerbated citrobacter rodentium-induced colitis.

59. Brunser O, Gotteland M. Pilot study: alterations
of barrier function.

60. Hooper LV, Wong MH, Thelin A, Hansson L, Falk
PG, Gordon JI. Molecular analysis of commensal
bacteria and host-microbial relationships in the intestine.

receptor gamma target gene encoding a novel angi-
opoietin-related protein associated with adipose dif-

62. Aronsson L, et al. Decreased fat storage by Lactoba-
acin-induced changes in intestinal mucus: study in

63. Zhang C, et al. Interactions between gut micro-
biota, host genetics and diet relevant to develop-
ment of metabolic syndromes in mice. ISME J.

64. Li C, Kearney JF Jr. AMP-activated protein kinase:
a stress-responsive kinase with implications for

65. Backhed F, Ley RE, Sonnenburg JL, Peterson DA,
Gordon JI. Host-lactobacillus mutualism in the human

receptors GPR41 and GPR43 are activated by pro-
prionate and other short chain carboxylic acids.

67. Le Poué E, et al. Functional characterization of
human receptors for short chain fatty acids and their
role in polymorphonuclear cell activation. J Biol Chem.

68. Samuel BS, et al. Effects of the gut microbiota on host
adiposity are modulated by the short-chain fatty-acid
binding G protein-coupled receptor, Gpr41. Proc Natl

69. Zaihs MS, et al. Role of GPR41 and GPR43 in lep-
tin secretory responses of murine adipocytes to short

70. Bjursell M, et al. Improved glucose control and
reduced body fat mass in free fatty acid receptor
2-deficient mice fed a high-fat diet. Am J Physiol

71. Madlowski KM, et al. Regulation of inflammatory
responses by gut microbiota and chemoattractant

protein-coupled receptor for short-chain fatty acids
suppresses colon cancer. Int J Cancer. 2011;

73. Cani PD, Delzenne NM. Interplay between obesity
and associated metabolic disorders: new insights
into the gut microbiota. Curr Opin Pharmacol.

74. Tilg H, Moschen AR. Adipocytokines: mediators
linking adipose tissue, inflammation and immu-

75. Membrez M, et al. The gut microbiota modulation
with norfloxacin and ampicillin enhances glucose
tolerance in mice. Am J Physiol Regul Integr Comp

76. Zhang C, et al. Interactions between gut micro-
biota, host genetics and diet relevant to develop-
ment of metabolic syndromes in mice. ISME J.

77. Rabot S, et al. Germ-free C57BL/6J mice are resis-
tant to high-fat-diet-induced insulin resistance
and have altered cholesterol metabolism. FASEB J.

78. Wu X, et al. Molecular characterization of the fac-

with type 2 diabetes differs from non-diabetic

80. Cani PD, et al. Selective increases of bifidobacteria
in gut microflora improve high-fat-diet-induced dia-
abetes in mice through a mechanism associated with

81. Vijay-Kumar M, et al. Metabolic syndrome and
altered gut microbiota in mice lacking Toll-like

82. Letran SE, et al. TLR-5-deficient mice lack basal
inflammatory and metabolic defects but exhibit
impaired CD4 T-cell responses to a flagellated

induced by T-bet deficiency in the innate immune

84. Freedland KB, Wilson C, Wolver TM. Adaptation
of colonic fermentation and glucagon-like peptide-I
secretion with increased wheat fibre intake for 1
year in hyperinsulinaemic human subjects. Br J

85. Hooda S, Matte JJ, Vasanthan T, Zijlstra RT.
Dietary oat beta-glucon reduces peak net glucose
flux and insulin production and modulates plasma
insulin in portal-vein catheterized growing pigs.

86. Regmi PR, van Kermep TA, Matte JJ, Zijlstra RT.
Starch with high amylose and low in vitro digest-
ibility increases short-chain fatty acid absorption,
reduces peak insulin secretion, and modulates incre-

87. Frank DN, St Amand AL, Feldman RA, Boedeker
EC, Harpaz N, Pace NR. Molecular-phylogenetic
categorization of microbial community imbal-
ances in human inflammatory bowel diseases. Proc

88. Tvede M, Rask-Madsen J. Bacteriotherapy for
chronic relapsing Clostridium difficile diarrhoea

89. Vrieze A, et al. Metabolic effects of transplanting gut
microbiota from lean donors to subjects with meta-